Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
PHILADELPHIA, and OXFORD, United Kingdom, Sept. 08, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences:
- James Noble, Adaptimmune’s chief executive officer, will present at the 2016 Morgan Stanley Global Healthcare Conference on Tuesday September 13, 2016 at 8:00AM EDT (1:00 PM BST). The conference is being held at the Grand Hyatt New York;
- Adrian Rawcliffe, Adaptimmune’s chief financial officer, will present at the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on Thursday September 29, 2016 at 8:30 AM EDT (1:30 PM BST). The conference is being held at the Lotte New York Palace hotel.
Adaptimmune’s presentations at these conferences will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conferences.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: [email protected]
